SUDA has had a busy couple of months, announcing approval for ZolpiMist in Australia by the Therapeutics Goods Administration (TGA) in July, as well as raising A$4.1m in additional capital. The TGA approval demonstrates SUDA’s compliance with Good Manufacturing Practice (GMP) as well as an ability to obtain regulatory approvals. This approval will assist SUDA’s current partners in their submissions in the territories for which they are responsible.
03 Sep 2020
Suda Pharmaceuticals - A TGA approval and a capital raise
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Suda Pharmaceuticals - A TGA approval and a capital raise
Arovella Therapeutics Limited (ALA:ASX) | 0 0 6.7% | Mkt Cap: 19.5m
- Published:
03 Sep 2020 -
Author:
Maxim Jacobs -
Pages:
5
SUDA has had a busy couple of months, announcing approval for ZolpiMist in Australia by the Therapeutics Goods Administration (TGA) in July, as well as raising A$4.1m in additional capital. The TGA approval demonstrates SUDA’s compliance with Good Manufacturing Practice (GMP) as well as an ability to obtain regulatory approvals. This approval will assist SUDA’s current partners in their submissions in the territories for which they are responsible.